| Q40177231 | A perspective on new beta-lactam antibiotics in pediatric patients. |
| Q38546483 | Adverse reaction to ceftriaxone in a 28-day-old infant undergoing urgent craniotomy due to epidural hematoma: review of neonatal biliary pseudolithiasis |
| Q33429288 | Antimicrobial therapy for pediatric patients |
| Q36216002 | Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval |
| Q40142949 | Ceftriaxone A Review of its Antibacterial Activity, Pharmacological Properties and Therapeutic Use |
| Q57800926 | Ceftriaxone absorption enhancement for noninvasive administration as an alternative to injectable solutions |
| Q30447780 | Ceftriaxone in treatment of serious infections. Meningitis |
| Q39835731 | Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life |
| Q35876822 | Cephalosporins in adult meningitis. |
| Q39685289 | Cephalosporins in the treatment of meningitis. |
| Q30437952 | Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review |
| Q37956835 | Clinical pharmacokinetics of antibacterial drugs in neonates |
| Q38730314 | Clinical pharmacokinetics of ceftriaxone |
| Q34193622 | Clinical pharmacokinetics of the third generation cephalosporins |
| Q34437719 | Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics |
| Q30451305 | Comparison of ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis |
| Q35756153 | Comparison of ceftriaxone and traditional therapy of bacterial meningitis |
| Q92411885 | Development of Rectodispersible Tablets and Granulate Capsules for the Treatment of Serious Neonatal Sepsis in Developing Countries |
| Q54239109 | Development of pneumococcal meningitis during ceftriaxone therapy. |
| Q53421512 | Effects of ceftriaxone on hydrocodone seeking behavior and glial glutamate transporters in P rats. |
| Q35126446 | Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae |
| Q38657914 | Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates |
| Q31043972 | How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach |
| Q90086277 | Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation |
| Q39383696 | In vitro antibiotic sensitivity pattern of common bacterial isolates from cases of acute bacterial meningitis with special reference to ceftriaxone |
| Q41587179 | Increased resistance to multiple antimicrobials and altered resistance gene expression in CMY-2-positive Salmonella enterica following a simulated patient treatment with ceftriaxone |
| Q54756488 | Intramuscular ceftriaxone versus ampicillin-chloramphenicol in childhood bacterial meningitis. |
| Q40833427 | Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in children |
| Q69426563 | Outpatient therapy for serious infections |
| Q34142328 | Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections |
| Q33724677 | Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. |
| Q34099810 | Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid |
| Q40686147 | Pharmacokinetics of anti-infective agents in paediatric patients |
| Q38093135 | Pharmacokinetics of antibacterial agents in the CSF of children and adolescents |
| Q37381432 | Pharmacokinetics of ceftriaxone |
| Q72390336 | Pharmacokinetics of ceftriaxone in neonates and infants with meningitis |
| Q27008185 | Pharmacokinetics of cephalosporins in the neonate: a review |
| Q68213793 | The cephalosporins |
| Q70175016 | The potential uses of ceftriaxone |
| Q59573978 | Validation of a Dried Blood Spot Ceftriaxone Assay in Papua New Guinean Children with Severe Bacterial Infections |
| Q69894349 | [Pharmacokinetics and tissue penetration of ceftriaxone] |